

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Form PTO-1449 (Modified)
(Use several sheets if necessary)**COMPLETE IF KNOWN**

Application Number	69/910,406
Confirmation Number	9683
Filing Date	July 19, 2001
First Named Inventor	Yoshihiro Sokawa
Group Art Unit	1648
Examiner Name	Wortman, Donna C.
Attorney Docket No.	55600-8004.US00

Sheet	1	of	1
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
MM			WO00/78266		Univ of Maryland College Park	12/28/2000		
J			WO96/35789		The Women's Research Institute	11/14/1996		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
MM		Clayette, P., et al., "IFN - tau, a new interferon type I with antiretroviral activity," <i>Pathologie Biologie</i> , 47:4 553-559 (1999).	
J		Saez-Royuela, F., et al., "Treatment of Chronic Non-A Non-B Hepatitis with High Doses of Recombinant IFN-ALPHA or Recobinant IFN-TAU," 40 th Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, IL, <i>Hepatology</i> , 10:4 646 (1989).	

EXAMINER

Mosley

DATE CONSIDERED

3/11/04

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).